Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Drug User Fees Will Begin With The Backlog

Executive Summary

FDA set aside fears that a separate fee for the application backlog would create administrative problems for its generic drug user fee program, instead choosing to use the queue of pending submissions to help gain more funding at launch.

Related Content

Inspection Improvements Could Help Fight Drug Shortages, Hospital Group Says
FDA Reshuffles Office Of Generic Drugs To Improve Performance
FDA Reshuffles Office Of Generic Drugs To Improve Performance
FDA, Industry Reach Agreement On Major Portions Of Generic User Fee Program
Reactivation Fee Is Proposed For Biosimilar INDs Placed On Hold
NDA, BLA Submissions Expected To Fall Again in FY 2011
How "Clean" Will PDFUA V Be? Rep. Pitts Explains His Vacuuming Technique
Generic User Fee Talks: Performance Metrics For Early Years Still Unresolved
Generic User Fees: API Manufacturers To Pay Less Than Finished Dose Firms
Generic User Fee Negotiators Struggling To Meet June Deadline





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts